<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154159">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01093066</url>
  </required_header>
  <id_info>
    <org_study_id>0908038</org_study_id>
    <secondary_id>2009-014264-19</secondary_id>
    <nct_id>NCT01093066</nct_id>
  </id_info>
  <brief_title>Prospective Multicentric Evaluation of a Bladder Preservation Strategy</brief_title>
  <acronym>ReChiVe</acronym>
  <official_title>Prospective Multicentric Evaluation of a Bladder Preservation Strategy Using a Combination of Neoadjuvant Chemotherapy and Optimal Bladder Transurethral Resection in Patients With a Urothelial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radical cystectomy is the treatment of choice for bladder infiltrative urothelium carcinoma.
      But the removal of the bladder reservoir has a major impact of the Quality of life.
      Neoadjuvant chemotherapy has been shown to be associated with an absolute 5% survival
      benefit. Two monocentric studies suggest that this neoadjuvant chemotherapy could be used in
      combination with an optimal transurethral bladder resection, in a strategy of bladder
      preservation, provided a complete response being obtained (about 50% in every trial using
      neoadjuvant MVAC protocol before a radical cystectomy). In those both studies with patients
      T2 to T4, the 5 years overall survival is above 65%, with more than 40% bladder preservation
      rate at 5 years.

      The feasibility and the efficacy of such an attitude in a multicentric trail using the most
      active regimen (in term of complete response in metastatic patients) is unknown. The chosen
      regimen is therefore the intensified MVAC which allows, with the use of G-CSF, to double the
      dose-intensity of Adriamycin and Cisplatinum, and to decrease by 30% the methotrexate and
      vinblastine dose-intensity.

      The efficacy and safety confirmation of such an approach could lead to consider it in
      patients motivated to retain a functional bladder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Every patient having signed the inform consent will have the following steps Maximal and
      optimal TURB using a standardized procedure. The TURB will always try to be optically
      complete.

      Neoadjuvant chemotherapy for 3 months with the intensified MVAC (6 cycles administered every
      2 weeks): METHOREXATE: 30 mg/m2 D1 - VINBLASTINE: 3 mg/m2 D2 - ADRIAMYCINE 30 mg/m2 D2 -
      CISPLATINE 70 mg/m2 D2. + G-CSF: 5 µg/kg from D4 to D10 New maximal standardized TURB at the
      end of the chemotherapy. In case of a lesion localized at the bladder dome, and if a maximal
      TURB appears to be unsafe, a partial cystectomy without lymph node dissection will be
      performed.

      If a complete response is obtained (no tumor cells in the bladder muscle on the last TURB),
      a surveillance will be proposed without any further treatment.

      Otherwise (tumor cells in the bladder muscle at the second TURB), a radical cystectomy will
      be done.

      If the balder is spared, the follow up will be as follow: clinical examination, CT, bladder
      endoscopy and urinary cytology every 6 months. The possible non muscle infiltrative bladder
      relapses will be treated according
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the 5 years bladder preservation rate (with or without intravesical non muscle infiltrative recurrences, treated by TURB only or intravesical instillations of either BCG or mytomicin C).</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>proportion of complete response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemotherapy tolerance in a neoadjuvant setting using the intensified MVAC</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary cystectomy rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (either infiltrative [≥ T2] or metastatic)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall bladder preservation rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>surgical resection and chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maximal and optimal TURB using a standardized procedure. The TURB will always try to be optically complete.
Neoadjuvant chemotherapy for 3 months with the intensified MVAC (6 cycles administered every 2 weeks): METHOREXATE: 30 mg/m2 D1 - VINBLASTINE: 3 mg/m2 D2 - ADRIAMYCINE 30 mg/m2 D2 - CISPLATINE 70 mg/m2 D2. + G-CSF: 5 µg/kg from D4 to D10 New maximal standardized TURB at the end of the chemotherapy. In case of a lesion localized at the bladder dome, and if a maximal TURB appears to be unsafe, a partial cystectomy without lymph node dissection will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>optimal TURB</intervention_name>
    <description>The TURB will always try to be optically complete.</description>
    <arm_group_label>surgical resection and chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  T2 clinical stage (no palpable mass under anesthesia after TURB) Absence of diffuse
             Cis (Cis on random bladder biopsies) Patients above 18, and below 70 years of age PS
             status ≤ 2 No previous treatment for a bladder muscle infiltrative carcinoma.
             Previous endovesical instillations for non muscle infiltrative lesions (pTa, pT1,
             Cis) are allowed.

        No metastases on tauraco-abdomina-pelvic CT scan (no node &gt; 1 cm) and bone scan.

        Normal biological values: neutrophils &gt; 1,5.109 /l, platelets &gt; 100. 109 /l, Alkaline
        Phosphatases &lt; 2 x N, bilirubin &lt; 1,5 N, Transaminases &lt; 1,5 x N, Creatinine clearance ≥
        60 ml/min Signed inform consent Patient belonging to a social security system.

        Exclusion Criteria:

        All other histology than urothelial carcinoma:

          -  primitive adenocarcinoma

          -  epidermoid carcinoma

          -  little cells carcinoma In situ diffuse carcinoma associated with urothelial carcinoma
             muscular infiltrating Tumor stade &gt; T2, T3 or T4 or pT4a (prostatitis) Serious
             cardiac, pulmonary, hepatitic, renal, digestive or neurological pathology which is
             non equilibrating or potential aggravating risk by treatment Cancer history or other
             actual cancer (except skin cancer) not remission or with an end of treatment inferior
             to 2 years Participation to another clinical trial in a delay inferior to 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas MOTTET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>clinique Mutualiste chirurgicale</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas MOTTET, MD</last_name>
    <email>nmottet@mutualite-loire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>RAVAUD Alain</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain RAVAUD, MD</last_name>
      <email>alain.ravaud@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Alain RAVAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hervé WALLERAND, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henri BENSADOUN</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henri BENSADOUN, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Henri BENSADOUN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence JOLY-LOBBEDEZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eric LECHEVALLIER</name>
      <address>
        <city>Marseille</city>
        <zip>13 385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric LECHEVALLIER, Dr</last_name>
      <email>elechevallier@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Eric LECHEVALLIER, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RIGAUD Jérôme</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme RIGAUD, Dr</last_name>
      <email>jrigaud@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Jérôme RIGAUD, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRANI Jacques</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques IRANI, Dr</last_name>
      <email>j.irani@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques IRANI, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>B DORE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Mutualiste Chirurgicale</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas MOTTET, Dr</last_name>
      <email>nmottet@mutualite-loire.com</email>
    </contact>
    <investigator>
      <last_name>Nicolas MOTTET, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BOMPAS Emmanuelle</name>
      <address>
        <city>Saint-herblain</city>
        <zip>44 805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle BOMPAS, MD</last_name>
      <email>e-bompas@nantes.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuelle BOMPAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GUILLOT Aline</name>
      <address>
        <city>Saint-priest En Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aline GUILLOT, MD</last_name>
      <email>aline.guillot@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Aline GUILLOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHEVREAU Christine</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine CHEVREAU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christine CHEVREAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SOULIE Michel</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel SOULIE</last_name>
      <email>soulie.m@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Michel SOULIE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GEOFFROY Lionel</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel GEOFFROY, MD</last_name>
      <email>l.geoffrois@nancy.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Florence JOLY-LOBBEDEZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 19, 2016</lastchanged_date>
  <firstreceived_date>March 24, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>urothelial carcinoma</keyword>
  <keyword>TURB</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
